Fig. 2

Comparison of clinical outcomes between patients with FL grade 1–2 and grade 3a. A-B Kaplan‒Meier curves of PFS (A) and OS (B) for FL1-2 and FL3a patients. The median PFS for FL1-2 patients (122 months, [95% CI: 44%-56%]), in comparison with FL3a patients (74 months; [95% CI: 45%-56%]); stratified P < 0.01. The median OS for FL1-2 and FL3a patients were both not reached. C-D Kaplan‒Meier curves of PFS (C) and OS (D) for FL1-2 and FL3a patients treated with R-CHOP regimen. 5-year PFS rate for FL1-2 patients who received R-CHOP therapy (67.2%, range 0.63–0.71), in comparison with FL3a patients who received R-CHOP therapy (53.6%, range 0.48–0.59); stratified P < 0.001. 5-year OS rate for FL1-2 patients who received R-CHOP therapy (92.3%, range 0.89–0.94), in comparison with FL3a patients who received R-CHOP therapy (91.4%, range 0.88–0.94); stratified P > 0.05